UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Section 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of August 2017
Commission File Number: 001-37569
STRONGBRIDGE BIOPHARMA plc
(Exact name of Registrant as specified in its charter)
900 Northbrook Drive
Suite 200
Trevose, PA 19053
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
On August 7, 2017, Strongbridge Biopharma plc (the “Registrant”) issued a press release providing certain updates and business highlights, as well as second quarter 2017 financial results.
The information contained in the press release is being furnished to the Commission and shall not be deemed incorporated by reference into any of the Registrant’s registration statements or other filings with the Commission.
Exhibits
Exhibit |
| Exhibit Table |
99.1 |
| Press Release issued by Strongbridge Biopharma plc, dated August 7, 2017. |